

(43) International Publication Date
7 April 2011 (07.04.2011)(10) International Publication Number
WO 2011/041461 A2

(51) International Patent Classification:

C07D 413/06 (2006.01) *A61K 31/4245* (2006.01)
C07D 413/12 (2006.01) *A61K 31/4427* (2006.01)
C07D 413/04 (2006.01) *A61P 11/06* (2006.01)
C07D 261/14 (2006.01) *A61P 35/00* (2006.01)
A61K 31/42 (2006.01)

(21) International Application Number:

PCT/US2010/050786

(22) International Filing Date:

29 September 2010 (29.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/247,877 1 October 2009 (01.10.2009) US

(71) Applicant (for all designated States except US): **AMIRA PHARMACEUTICALS, INC.** [US/US]; 9535 Waples Street Suite 100, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLARK, Ryan** [US/US]; 10961 Canis Lane, San Diego, CA 92126 (US). **STEARNS, Brian, Andrew** [US/US]; 157 Beechtree Drive, Encinitas, CA 92024 (US). **ZHAO, Lucy** [US/US]; 11254 Caminito Corriente, San Diego, CA 92128 (US). **SEIDERS, Thomas, Jon** [US/US]; 5257 Soledad Mountain Road, San Diego, CA 92109 (US). **VOLKOTS, Deborah** [US/US]; 8212 Regents Rd #204, San Diego, CA 92122 (US). **ARRUDA, Jeannie, M.** [US/US]; 3611 Florida St. #4, San Diego, CA 92104 (US). **ZALATAN, David Nathan** [US/US]; 1425 Ocean Avenue, Apt. 1, Del Mar, CA 92014 (US).

(74) Agents: **WILSON SONSINI GOODRICH & ROSATI** et al.; 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

[Continued on next page]

(54) Title: POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

(57) Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.




FIGURE 1



ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))